Detalhe da pesquisa
1.
The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB).
Alzheimers Dement
; 20(1): 695-708, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37774088
2.
Expectations and clinical meaningfulness of randomized controlled trials.
Alzheimers Dement
; 19(6): 2730-2736, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36748826
3.
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
N Engl J Med
; 378(4): 321-330, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29365294
4.
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Alzheimers Dement
; 14(4): 535-562, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29653606
5.
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.
Alzheimers Dement
; 14(4): 563-575, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29653607
6.
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
N Engl J Med
; 370(4): 311-21, 2014 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24450890
7.
Statistical properties of continuous composite scales and implications for drug development.
J Biopharm Stat
; 27(6): 1104-1114, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28402165
8.
Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials.
Alzheimers Dement
; 13(10): 1117-1124, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28365320
9.
A phase 3 trial of semagacestat for treatment of Alzheimer's disease.
N Engl J Med
; 369(4): 341-50, 2013 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-23883379
10.
Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer's disease clinical trial cohort.
Alzheimers Dement
; 12(9): 977-986, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27109039
11.
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
Alzheimers Dement
; 12(2): 110-120, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26238576
12.
Challenges, solutions, and recommendations for Alzheimer's disease combination therapy.
Alzheimers Dement
; 12(5): 623-30, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27017906
13.
Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB).
Alzheimers Dement
; 11(7): 840-9, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26194317
14.
"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia".
Alzheimers Dement
; 15(1): 153-157, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30642435
15.
National Institute on Aging - Alzheimer's Association Research Framework lays the groundwork for deeper understanding of Alzheimer's disease.
Alzheimers Dement
; 14(2): 261-262, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29413643
16.
Improving Alzheimer's disease phase II clinical trials.
Alzheimers Dement
; 9(1): 39-49, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23164548
17.
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease.
Alzheimers Dement
; 9(2): 123-131.e1, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23411394
18.
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
Alzheimers Dement
; 9(4): 438-44, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23809364
19.
Decision making in clinical trials: Interim analyses, innovative design, and biomarkers.
Alzheimers Dement (N Y)
; 9(4): e12421, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37867532
20.
Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies.
Alzheimers Dement
; 8(5): 407-16, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22138370